Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group

Medicine and Dentistry

• Oncology 100%
• Prostate Cancer 100%
• Prostate Specific Antigen 100%
• T-Cell Response 10%
• Clinical Trial 5%
• T Cell 5%
• Adverse Event 5%
• Progression Free Survival 5%
• Adaptive Immunity 5%
• Antigen Antibody Complex 5%
• Local Therapy 5%
• Fowlpox Virus 5%
• Fowlpox 5%
• Antigen Response 5%
• Vaccinia Virus 5%
• Vaccinia antibody 5%
• Vaccinia 5%
• Diseases 5%
• Treatment Group 5%
• Randomized Clinical Trials 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Prostate Specific Antigen 100%
• Tolerability 5%
• Clinical Trial 5%
• Randomized Clinical Trial 5%
• Adverse Event 5%
• Progression Free Survival 5%
• Fowlpox Virus 5%
• Fowlpox 5%
• Vaccinia Virus 5%
• Vaccinia antibody 5%
• Vaccinia 5%
• Diseases 5%
• Treatment Group 5%

Immunology and Microbiology

• Prostate Specific Antigen 100%
• T Cell 15%
• Antibody Titer 10%
• Adaptive Immune System 5%
• Immune Complex 5%
• Antigen Response 5%
• Progression Free Survival 5%
• Vaccinium 5%
• Vaccinia Virus 5%
• Fowlpox Virus 5%
• Vaccinia antibody 5%